New pathways of protective and pathological host defense to mycobacteria

Trends in Microbiology

Volumn 20, Issue 9, 2012, Pages 419-428

  Ottenhoff, Tom H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Genome wide screens; Inflammation; Innate immunity; Leprosy; Protection; T cells; Tuberculosis

Indexed keywords

BCG VACCINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CD163 ANTIGEN; COMPLEMENT RECEPTOR; GAMMA INTERFERON; HLA E ANTIGEN; IMATINIB; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 4; LECTIN; LEUKOTRIENE A4 HYDROLASE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MANNOSE RECEPTOR; MONOCYTE INDUCIBLE C TYPE LECTIN; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; POLYPEPTIDE ANTIBIOTIC AGENT; RETINOIC ACID INDUCIBLE PROTEIN I; RETINOIC ACID INDUCIBLE PROTEIN I LIKE RECEPTOR; SCAVENGER RECEPTOR; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALOX5 GENE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AUTOPHAGY; BACTERIAL VIRULENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG MECHANISM; ENZYME ACTIVITY; GENE; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IGRM GENE; IL1 RECEPTOR ANTAGONIST GENE; IL10 GENE; IMMUNOREGULATION; INFECTION RESISTANCE; INNATE IMMUNITY; LEPROSY; LTA4H GENE; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER T CELL; NOD2 GENE; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLC11A1 GENE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TLR8 GENE; TNF GENE; TUBERCULOSIS; VDR GENE;

DISEASE RESISTANCE; GENETIC PREDISPOSITION TO DISEASE; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; LEPROSY; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; T-LYMPHOCYTE SUBSETS;

CORYNEBACTERINEAE;

EID: 84865792720     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2012.06.002     Document Type: Review

References (98)

1. WHO (2009) Global Tuberculosis Control: Epidemiology, Strategy, Financing, WHO report 2009.
2. Britton W.J., Lockwood D.N. Leprosy. Lancet 2004, 363:1209-1219.
3. Ottenhoff T.H., Kaufmann S.H. Vaccines against tuberculosis: where are we and where do we need to go?. PLoS Pathog. 2012, 8:e1002607.
4. Ottenhoff T.H., et al. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat. Genet. 2002, 32:97-105.
5. Mutis T., et al. Analysis of cytokine production by Mycobacterium-reactive T cells. Failure to explain Mycobacterium leprae-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. J. Immunol. 1993, 150:4641-4651.
6. Gallegos A.M., et al. A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS. Pathog. 2011, 7:e1002052.
7. Salgame P., et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991, 254:279-282.
8. Potian J.A., et al. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J. Exp. Med. 2011, 208:1863-1874.
9. Maglione P.J., Chan J. How B cells shape the immune response against Mycobacterium tuberculosis. Eur. J. Immunol. 2009, 39:676-686.
10. Jacobsen M., et al. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J. Mol. Med. 2007, 85:613-621.
11. Joosten S.A., et al. Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immun. 2012, 13:71-82.
12. Liu L., et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 2011, 208:1635-1648.
13. Puel A., et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 2010, 207:291-297.
14. Khader S.A., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 2007, 8:369-377.
15. Okamoto Y.Y., et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J. Immunol. 2010, 184:4414-4422.
16. Scriba T.J., et al. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J. Immunol. 2008, 180:1962-1970.
17. Cruz A., et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J. Exp. Med. 2010, 207:1609-1616.
18. Torrado E., et al. Cellular response to mycobacteria: balancing protection and pathology. Trends Immunol. 2011, 32:66-72.
19. Wilson M.S., et al. Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections. J. Immunol. 2010, 184:4378-4390.
20. Ye Z.J., et al. Differentiation and recruitment of Th9 cells stimulated by pleural mesothelial cells in human Mycobacterium tuberculosis infection. PLoS ONE 2012, 7:e31710.
21. Jeyanathan M., et al. Airway luminal T cells: a newcomer on the stage of TB vaccination strategies. Trends Immunol. 2010, 31:247-252.
22. Jeyanathan M., et al. Murine airway luminal antituberculosis memory CD8 T cells by mucosal immunization are maintained via antigen driven in situ proliferation, independent of peripheral T cell recruitment. Am. J. Respir. Crit. Care Med. 2010, 181:862-872.
23. Ronan E.O., et al. Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS ONE 2009, 4:e8235.
24. Tchilian E.Z., et al. Simultaneous immunization against tuberculosis. PLoS ONE 2011, 6:e27477.
25. Gold M.C., et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol. 2010, 8:e1000407.
26. Grotzke J.E., et al. The Mycobacterium tuberculosis phagosome is a HLA-I processing competent organelle. PLoS Pathog. 2009, 5:e1000374.
27. Joosten S.A., et al. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T cells with cytotoxic as well as regulatory activity. PLoS Pathog. 2010, 6:e1000782.
28. Caccamo N., et al. Analysis of Mycobacterium tuberculosis-specific CD8 T cells in patients with active tuberculosis and in individuals with latent infection. PLoS ONE 2009, 4:e5528.
29. Tang S.T., et al. Genome-based in silico identification of new Mycobacterium tuberculosis antigens activating polyfunctional CD8+ T cells in human tuberculosis. J. Immunol. 2011, 186:1068-1080.
30. Kagina B.M., et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am. J. Respir. Crit. Care Med. 2010, 182:1073-1079.
31. Lewinsohn D.A., et al. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS. Pathog. 2007, 3:1240-1249.
32. Commandeur S., et al. Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation-promoting factors in long-term latently infected individuals. Clin. Vaccine Immunol. 2011, 18:676-683.
33. Stenger S., et al. Granulysin: a lethal weapon of cytolytic T cells. Immunol. Today 1999, 20:390-394.
34. Urdahl K.B., et al. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol. 2011, 4:288-293.
35. Wolf A.J., et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 2008, 205:105-115.
36. Reiley W.W., et al. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10961-10966.
37. Gallegos A.M., et al. Delayed protection by ESAT-6-specific effector CD4+ T cells after airborne M. tuberculosis infection. J. Exp. Med. 2008, 205:2359-2368.
38. Egen J.G., et al. Intravital imaging reveals limited antigen presentation and T cell effector function in mycobacterial granulomas. Immunity 2011, 34:807-819.
39. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 2009, 27:393-422.
40. Modlin R.L., et al. Genetically restricted suppressor T-cell clones derived from lepromatous leprosy lesions. Nature 1986, 322:459-461.
41. Ottenhoff T.H., et al. Regulation of mycobacterial heat-shock protein-reactive T cells by HLA class II molecules: lessons from leprosy. Immunol. Rev. 1991, 121:171-191.
42. Shafiani S., et al. Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J. Exp. Med. 2010, 207:1409-1420.
43. Savage N.D., et al. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J. Immunol. 2008, 181:2220-2226.
44. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
45. Montoya D., et al. Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe 2009, 6:343-353.
46. Verreck F.A., et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:4560-4565.
47. Murphy K.M., Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat. Immunol. 2010, 11:674-680.
48. Scriba T.J., et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur. J. Immunol. 2010, 40:279-290.
49. van Dissel J.T., et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010, 28:3571-3581.
50. Ottenhoff T.H., et al. Ten challenges for TB biomarkers. Tuberculosis (Edinb.) 2012, 92(Suppl. 1):S17-S20.
51. Aagaard C., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 2011, 17:189-194.
52. Leyten E.M., et al. Human T cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect. 2006, 8:2052-2060.
53. Black G.F., et al. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin. Vaccine Immunol. 2009, 16:1203-1212.
54. Dye C., Williams B.G. The population dynamics and control of tuberculosis. Science 2010, 328:856-861.
55. Sweeney K.A., et al. A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat. Med. 2011, 17:1261-1268.
56. Cobat A., et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J. Exp. Med. 2009, 206:2583-2591.
57. Harding C.V., Boom W.H. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat. Rev. Microbiol. 2010, 8:296-307.
58. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
59. Holscher C., et al. Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function for TLR2, -4 and -9. Eur. J. Immunol. 2008, 38:680-694.
60. Davila S., et al. Genetic association and expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis. PLoS Genet. 2008, 4:e1000218.
61. Ishikawa E., et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J. Exp. Med. 2009, 206:2879-2888.
62. Dorhoi A., et al. The adaptor molecule CARD9 is essential for tuberculosis control. J. Exp. Med. 2010, 207:777-792.
63. Marakalala M.J., et al. The Syk/CARD9-coupled receptor Dectin-1 is not required for host resistance to Mycobacterium tuberculosis in mice. Microbes Infect. 2011, 13:198-201.
64. Ferwerda G., et al. NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog. 2005, 1:279-285.
65. Kim B.H., et al. A family of IFN-gamma-inducible 65-kD GTPases protects against bacterial infection. Science 2011, 332:717-721.
66. Sturgill-Koszycki S., et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994, 263:678-681.
67. Deretic V. Autophagy in infection. Curr. Opin. Cell Biol. 2010, 22:252-262.
68. Levine B., et al. Autophagy in immunity and inflammation. Nature 2011, 469:323-335.
69. Gutierrez M.G., et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004, 119:753-766.
70. Singh S.B., et al. Human IRGM induces autophagy to eliminate intracellular mycobacteria. Science 2006, 313:1438-1441.
71. Petruccioli E., et al. Specific T cells restore the autophagic flux inhibited by Mycobacterium tuberculosis in human primary macrophages. J. Infect. Dis. 2012, 205:1425-1435.
72. Travassos L.H., et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol. 2010, 11:55-62.
73. Keane J., et al. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J. Immunol. 2000, 164:2016-2020.
74. Divangahi M., et al. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat. Immunol. 2010, 11:751-758.
75. Tobin D.M., et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010, 140:717-730.
76. Tobin D.M., et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012, 148:434-446.
77. Ma F., et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat. Immunol. 2011, 12:861-869.
78. Kuijl C., et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 2007, 450:725-730.
79. Jayaswal S., et al. Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS. Pathog. 2010, 6:e1000839.
80. Kumar D., et al. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 2010, 140:731-743.
81. Casanova J.L., Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol. 2002, 20:581-620.
82. Ottenhoff T.H., et al. Control of human host immunity to mycobacteria. Tuberculosis (Edinb.) 2005, 85:53-64.
83. Intemann C.D., et al. Autophagy gene variant IRGM-261T contributes to protection from tuberculosis caused by Mycobacterium tuberculosis but not by M. africanum strains. PLoS. Pathog. 2009, 5:e1000577.
84. Thye T., et al. Common variants at 11p13 are associated with susceptibility to tuberculosis. Nat. Genet. 2012, 44:257-259.
85. Zhang F.R., et al. Genome wide association study of leprosy. N. Engl. J. Med. 2009, 361:2609-2618.
86. Ottenhoff T.H., de Vries R.R. HLA class II immune response and suppression genes in leprosy. Int. J. Lepr. Other Mycobact. Dis. 1987, 55:521-534.
87. Netea M.G., Joosten L.A. A NOD for autophagy. Nat. Med. 2010, 16:28-30.
88. Zhang F., et al. Identification of two new loci at IL23R and RAB32 that influence susceptibility to leprosy. Nat. Genet. 2011, 43:1247-1251.
89. Napier R.J., et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 2011, 10:475-485.
90. Yuk J.M., et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009, 6:231-243.
91. Cobat A., et al. High heritability of antimycobacterial immunity in an area of hyperendemicity for tuberculosis disease. J. Infect. Dis. 2010, 201:15-19.
92. Berry M.P., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
93. Darrah P.A., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 2007, 13:843-850.
94. Harari A., et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat. Med. 2011, 17:372-376.
95. Sutherland J.S., et al. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur. J. Immunol. 2009, 39:723-729.
96. Caccamo N., et al. Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur. J. Immunol. 2010, 40:2211-2220.
97. Gaseitsiwe S., et al. Peptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB10101, DRB11501, and DRB10401. Clin. Vaccine Immunol. 2010, 17:168-175.
98. Geluk A., et al. ML1419c peptide immunization induces Mycobacterium leprae-specific HLA-A0201-restricted CTL in vivo with potential to kill live mycobacteria. J. Immunol. 2011, 187:1393-1402.